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Opinion statement
Multiple sclerosis (MS) is an inflammatory-demyelinating disease of the central nervous
system that may entail severe levels of disability in the long term. However, independently
of the level of disability, MS patients frequently experience severe fatigue that can be as
disabling as objective neurological deficits. For that reason, it is mandatory to perform an
early diagnosis of MS-related fatigue and start a suitable treatment as soon as possible. In
clinical practice, MS-related fatigue should be assessed and managed by a multidisciplin-
ary team involving neurologists, MS nurses, occupational therapists, and physiotherapists.
When assessing a person with MS-related fatigue, the first step is to rule out potential
triggers or causes of fatigue, which may be related to MS, such as urinary dysfunction,
pain, or muscular spasms leading to a sleep disorder, or unrelated to it. Once these causes
have been ruled out and appropriately tackled, a careful therapeutic intervention needs to
be decided. Therapeutic interventions for MS-related fatigue can be pharmacological or
non-pharmacological. Regarding the pharmacological treatments, although many drugs
have been tested in clinical trials, only amantadine is currently recommended for this
indication. Regarding the non-pharmacological approaches, they can be broadly divided
into physical, psychological, and mixed physical/psychological interventions. Several
studies, many of them randomised clinical trials, support the use of all these types of
non-pharmacological interventions to treat MS-related fatigue. Recent publications sug-
gest that the implementation of mixed approaches, which have a naturally comprehensive
nature, may have excellent results in clinical practice, in relation not only to fatigue levels
but also to more general aspects of MS.
Introduction
Multiple sclerosis (MS) is an inflammatory-
demyelinating disease of the central nervous system that
is considered one of themost frequent causes of disability
in the young adult [1]. In 85 % of the cases, MS starts as a
relapsing-remitting disease. In this form of the condition,
the first clinical attack, called clinically isolated syndrome, is
followed by a number of relapses, after which there is
generally a good recovery. After 15–20 years of symptom
onset, there may appear a progressive clinical deteriora-
tion that is not related to the presence of clinical relapses,
which is called secondary progressive MS (SPMS). In
around 15 % of the cases, MS starts as a progressive
condition called primary progressive MS (PPMS) [2].
Neurological disability in both progressive forms of
MS mainly occurs at the expense of a progressive spastic
paraparesis, whichmay eventually affect the upper limbs,
and which can be accompanied by bladder and bowel
dysfunction. Besides, a progressive brainstem/cerebellar
syndromemay also be observed. Yet, apart from all these
objective neurological deficits, disability in MS can also
appear as a consequence of rather subjective symptoms
such as fatigue [3•, 4•].
Fatigue in MS is extremely common. It may affect up
to 80 % of the people with MS [5], and can be severe in
up to 65–70 % of them [6, 7]. Importantly, it tends to
persist over time once it appears [8]. Up to now, there is
no consensus for the definition of fatigue, although
Lapierre and Hum recently defined it as Bsubjective lack
of physical and/or mental energy that is perceived by the
individual or caregiver to interfere with usual or desired
activities^ [9]. It can have an important impact on the
quality of life of people with MS, and, in some cases, can
be perceived as disabling as loss of power in the limbs or
walking issues. Of note, fatigue does not appear more
frequently in those people with progressive forms of MS,
especially PPMS, but instead it is more commonly report-
ed amongst non-stable patients with relapse-onset MS
[7], suggesting that its appearance is not necessarily relat-
ed to objective neurological progression [8].
Fatigue in MS can be broadly divided into primary
and secondary fatigue [3•]. Primary fatigue refers to that
fatigue that appears without an apparent cause and it is
specific of MS. Instead, secondary fatigue appears as a
consequence of another condition, even if that is related
to MS, and could theoretically appear in any other con-
dition different from MS [10].
The pathological processes underlying MS-
related fatigue are not yet well known. Some of
the mechanisms proposed include structural ab-
normalities in deep grey matter regions [11, 12]
and dysfunction of brain networks involving deep
grey matter and cortex [11, 13, 14]. A recent re-
view paper suggested that the fact that all these
grey matter structures were associated with MS-
related fatigue could be pointing at an imbalance
in dopamine metabolism [15]. However, this hy-
pothesis needs to be confirmed. Since a better
understanding of these mechanisms will imply
greater chances of finding effective treatments,
more research in this field is guaranteed.
Clinical aspects of MS-related fatigue
In clinical practice, the first step is to investigate whether there is an underlying
cause or trigger for the fatigue, which needs to be treated before starting any
specific treatment for it. Causes and triggers of fatigue may be related to MS,
such as pain, night spasms and urine dysfunction, which can lead to sleep
disturbances and increased tiredness, or being unrelated toMS, as it is described
in Table 1.
Once possible underlying causes of fatigue have been ruled out, fatiguemust be
tackled through a multidisciplinary approach, involving neurologists, MS nurses,
occupational therapists and physiotherapists. This multidisciplinary team will
quantify the level of fatigue, which will be useful for future treatment monitoring.
This team will also identify the best combination of therapeutic options for each
individual, based on the severity of the fatigue and the presence of comorbidities.
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Quantification of the level of fatigue and its impact on day-to-day life can be
done through different scales (Table 2). The most commonly used are the Fatigue
Severity Scale (FSS) [16] and the Modified Fatigue Impact Scale (MFIS) [17], in the
setting of both clinical practice and clinical trials [18••]. Whereas FSS can be
Table 1. Possible causes and common triggers of fatigue in people with MS
Causes Clinical red flags Diagnostic procedures
Causes related to MS
Depression Low mood Neuropsychological assessment
Sleep disorders Excessive sleepiness, clinical features
of conditions leading to sleep
disorders, such
as anxiety sleep apnoea, obesity
Assessment by sleep disorders specialist
Pain, muscular spasms Pain or increased muscular tone during
examination
Anamnesis, clinical examination
Bladder dysfunction such as
nocturia, and urinary tract
infections
High temperature Temperature assessment, urine culture,
assessment by the urologist or the
bladder nurse specialist
Medication side effects Recent start of a new drug or increase
dose of previous medication
Anamnesis
Causes not related to MS
Anaemia Pale skin/conjunctivae Determination of haemoglobin levels
in blood
Thyroid dysfunction:
hypo/hyperthyroidism
Recent changes in weight, hair loss,
blood pressure
Determination of thyroid hormone
levels in blood
Medication side effects Recent start of a new drug or increase
dose of previous medication
Anamnesis
Table 2. Commonly used fatigue scales
Scale Reference Description Comments
Fatigue Severity Scale
(FSS)
Krupp et al. Arch Neurol
1989
9 questions, with scores from 1
(strongly disagree) to 7
(strongly agree)
Easy to answer
Available online
Modified Fatigue
Impact Scale
(MFIS)
Fisk et al. Canadian
Journal of Neurological
Sciences 1994
21 questions, with scores from 0
(never) to 4 (almost always), which
can be divided into 3
categories: physical,
cognitive, and psychosocial
Easy to answer
Available online
Provides information on
3 dimensions of fatigue:
physical, cognitive, and
psychosocial
Visual Analogue
Scale (VAS) for
fatigue
Kos et al. BMC Neurol
2006
10 cm straight line with equally
distant numbers from 0 to 10
printed, where the individual
must indicate to what extent
fatigue is severe (0= very
severe, 10=no fatigue)
Easy to answer
It may be difficult to
interpret (no specific
domains of fatigue
are explored)
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answered very quickly (only 9 questions), whichmay be very convenient in clinical
practice, MFIS requires a bit more time (21 questions) but can give a more precise
description of the impact of the fatigue on the subject’s day-to-day activities. For
example, the questions contained in MFIS can be divided into three categories:
physical, cognitive, and psychosocial. Therefore, for a given subject, not only a
global fatigue score will be given but also separate scores for these three domains.
These different scores may be useful to monitor therapeutic interventions, which
may be more oriented to tackle certain domains of the fatigue than others [17].
Another scale of fatigue that has been frequently used in clinical trials is the visual
analogue scale for fatigue, which is easy to administer and allows a very rapid
assessment of fatigue [19]. However, its interpretation may be more difficult than
that of more structured scales, and its reproducibility has proved to be only
moderate, with an intraclass correlation coefficient below 0.7 [19].
Apart from the scales designed to specifically measure fatigue, there are some
other, more general, scales that contain some questions to assess fatigue amongst
other aspects of the underlying condition, such as the Expanded Disability Status
Scale (EDSS) [20] or the Guy’s Neurological Disability Scale (GNDS) [21]. These
scales can be useful to give an overall measure of disability, and, in particular, the
EDSS has been—by far—the most commonly used disability scale in MS, in both
clinical practice and clinical trials. However, they are not ideal to measure and
monitor fatigue and other, more specific, scales are preferred. Finally, the SF-36
scale (i.e. the MOS 36-item short-form health survey) [22], a general scale to
measure quality of life in people not necessarily diagnosed with MS, has also
frequently used in clinical trials for MS fatigue, especially in relation to its items
related to physical activity [23].
Pharmacological treatments
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Pharmacological treatments for fatigue in MS are summarised in Table 3.
Amongst them, the most commonly used is amantadine. Its main mechanism
of action is not yet fully understood, although its effects in fatigue seem to be
related to its dopaminergic effects, supporting the dopamine imbalance theory
for MS-related fatigue abovementioned [15]. To date, at least seven randomised
clinical trials (RCTs) have compared amantadine with placebo [24–30] and one
RCT has compared amantadine with aspirin [31]. In general, all trials that
compared amantadine with placebo showed a significant effect of amantadine
on fatigue. However, the results of these trials need to be taken with caution due
to the low number of participants included in the trials, i.e. between 22 and 86
participants per trial, and the short duration of the interventions, which lasted
between 3 and 6 weeks. The clinical trial that compared aspirin (500 mg
daily orally) with amantadine in people with MS-related fatigue did not show
differences between the two drugs. This trial, which had a crossover design and
included 54 MS patients, showed a similar significant ability to decrease the
levels of fatigue over time for amantadine and aspirin [31]. Importantly, since
there was no placebo group, the results of this trial are difficult to interpret and
require further research to better characterise the role of these two drugs in
MS-related fatigue [31].
The daily dose of amantadine used in all published trials was 200mg, which
is the now accepted dose of amantadine for MS fatigue [18••]. Of note,
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amantadine is the only oral treatment that is currently recommended by the
National Institute for Health and Care Excellence (NICE) for the treatment of
MS-related fatigue [18••].
Modafinil, a drug currently approved for the treatment of attention-deficit
hyperactivity disorder (ADHD) and narcolepsy, has also been frequently eval-
uated in clinical trials for patients withMS-related fatigue. In 2002, Rammohan
et al. published a 9-week single-blind clinical trial where 72 patients received
placebo for the first 2 weeks, modafinil 200 mg daily for the following 2 weeks,
modafinil 400 mg daily for the following 2 weeks, and again placebo for the
final 3 weeks [32]. This trial showed a significant improvement in fatigue scores
when patients were receivingmodafinil 200mgper day, although no significant
treatment effect was seen during the period when patients were receiving
modafinil 400 mg per day. A few years alter, a randomised placebo-controlled
double-blind clinical trial with a parallel arm design and carried out with 110
patients showed no significant effect of modafinil (up to 400 mg daily), given
during a period of 5 weeks, on MS-related fatigue [33]. In 2009, another
randomised placebo-controlled trial evaluating the effect of modafinil and
carried out in 21 MS patients was published. This time, the drug, which was
given during 8 weeks, showed a significant effect not only on fatigue scores but
also on a motor task of the upper limbs (the 9-hole peg test [34]), and a
cognitive test. Interestingly, it also showed an increase in the amplitudes of
motor evoked potentials, suggesting modafinil might have an effect at the level
of motor cortex function [35]. However, in 2011, the results of a much larger
trial, which included 121 MS patients and also evaluated modafinil 200 mg
daily over 8 weeks, showed, in general, negative results [36]. Finally, in 2015, a
very small trial again showed no effect of modafinil on fatigue scores, although
some effects on cognitive outcomes were observed [37]. Thus, the overall
evidence supporting the effect of modafinil on MS-related fatigue is weak, and
in the last edition of the NICE guidelines modafinil was not included as a
recommended treatment for MS-related fatigue [18••].
Pemoline, a drug with some similarities withmodafinil for its dopaminergic
effects and its initial approval for the treatment of ADHD and narcolepsy, has
also been tested in clinical trials for MS-related fatigue, with overall negative
results [26, 27, 38]. Besides, it has been withdrawn from the market and is no
longer available for ADHD or narcolepsy either due to its side-effect profile,
since it has been associated to fatal liver failure.
The effect of 4-aminopyridine and its related compound, 3,4-
diaminopridinine on different aspects of MS has been frequently assessed over
the last 25 years. The 4-aminopyridine (also known as fampridine) is a potas-
sium channel blocker and therefore increases the duration of the action po-
tential, which translates into an increase in muscle strength. Apart from this
peripheral effect, some authors have also proposed a central effect, after ob-
serving an increase in the bold signal of a motor-task functional magnetic
resonance imaging performed after the administration of the related compound
3,4-diaminopridinine, as compared to that observed after the administration of
placebo [39].
The evaluation of the efficacy of 4-aminopyridine on different symptomatic
aspects of MS, including MS fatigue, started around 25 years ago [40–43]. In
1992, a clinical trial comparing 4-aminopyridine and placebowas published. In
this trial, which included 70 participants, those who took active treatment
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showed an improvement on the EDSS and a subjective improvement of fatigue
levels, with positive consequences in the ability to carry out day-to-day activities
[42]. During the following years, the results of this trial were somehow con-
firmed, but only in non-randomised studies [40, 41]. In 2001, the results of a
new randomised placebo-controlled trial double blind clinical trial were pub-
lished. This was a small crossover trial, with 54 individuals included, where the
effects of 4-aminopyridine were evaluated. This trial did not show significant
differences between active and placebo arms in terms of fatigue scores, EDSS
and cognitive scores. Interestingly, though, it did show an improvement in the
fatigue levels of those subjects with the highest blood levels of 4-
aminopyridine, implying a dose-response relationship, a key element to sup-
port a therapeutic effect on fatigue levels, as had been suggested in previous
studies [43]. However, in the clinical trials that have been published more
recently, it seems that this drug, although effective in improving walking speed,
does not have a clear effect on fatigue [44–46].
4-aminopyridine is considered to be quite safe and well tolerated. However,
some side effects, mainly neurological, may appear. These include insomnia,
anxiety, dizziness, paraesthesia, tremors, headache, asthenia and epileptic sei-
zures [44–48]. Apart from these, other side effects might also appear. For that
reason, before starting this or any other drug, it is always convenient to check the
document issued by the European Medicines Agency (EMEA) describing the
summary of the product characteristics [49].
Antidepressants have also been tried for the treatment of fatigue in MS. In
particular, a RCT compared paroxetinewith placebo [23], showing some beneficial
effects of paroxetine as compared with placebo in terms of the mental subscale of
SF-36, and the cognitive and psychosocial subscales of MFIS. However, the results
of this trial need to be interpreted with caution given that only 42 patients were
enrolled in the study and also because paroxetine did not seem to have an effect on
the physical scales of the SF-36 and theMFIS [18••].On the other hand, paroxetine
is quite a well-tolerated drug [50], whose main side effects are shown in Table 3.
L-carnitine has also been evaluated to treat MS-related fatigue. It is an amino
acid derivative involved in the metabolism of lipids and is a key element in
mitochondrial energy production [51]. For this reason, it was believed it could
improve fatigue levels in patients with chronic conditions [52]. At least three
studies have evaluated the efficacy of L-carnitine in MS-related fatigue [28, 53, 54],
although only two of themwere randomised trials [28, 53]. In the first one of these
two trials [53], which had a crossover design, acetyl L-carnitine 2 g/day was
compared to amantadine 200 mg/day in a group of 36 patients (30 finished the
trial). Treatments were given for 3 months to all patients, with a washout period
between them of also 3months. Although this trial showed some beneficial effects
of L-carnitine as compared to amantadinewith regard to FSS scores, the fact that no
placebo group was used together with the low number of participants enrolled
imply that the results must be taken with caution [51]. The second one of these
trials [28], which had a parallel arm design and included 60 patients, compared L-
carnitine 2 g/day, amantadine 200 mg/day, and modafinil 200 mg/day with
placebo in terms of their ability to improveMS fatigue. At the end of the trial, only
amantadine showed a significant beneficial effect versus placebo. Although the
group on L-carnitine had better scores than the placebo group, the differences were
not significant, maybe indicating lack of power. Instead, the group on modafinil
showed very similar fatigue scores to the placebo group, suggesting no beneficial
effect of modafinil [28]. Again, the evidence supporting L-carnitine to treat MS-
related fatigue is weak, and this treatment is not currently recommended by NICE
guidelines for this purpose [18••].
Other pharmacological approaches have also beenmentioned in the literature,
such as vitamin B12 intramuscular injections. However, in the NICE guidelines,
there is a clear recommendation of not offering this or other drugs for which
scientific evidence is lacking to treat MS-related fatigue [18••].
Non-pharmacological treatments
Once triggers of fatigue are identified and tackled [55], it is crucial to set relevant
and achievable goals before starting any therapeutic intervention. Generally, the
multidisciplinary team, especially the occupational therapists and physiother-
apists, will help the patient to set these goals. In many cases, these goals will be
related to instrumental activities of day-to-day life. Besides, they will need to be
rather short-term goals in order to make their achievement more feasible [56].
Finally, a convenient non-pharmacological intervention will be agreed for a
given individual. These interventions can be broadly divided into physical,
psychological/cognitive, and mixed approaches [18••].
Amongst the physical approaches, one of the most frequently assessed has
been aerobic exercise. In 1992, the results of a very well designed trial were
published. It included 54 MS patients, which were randomly divided into two
groups: exercise vs. no exercise. The intervention lasted for 15 weeks, and the
group assigned to exercise improved on almost all clinical scores and biological
markers except for the FSS scores, which remained unchanged for both groups
throughout the trial [57]. However, a more recent trial did show beneficial
effects for aerobic exercise as compared to placebo on MS fatigue. In particular,
this trial compared physiotherapist-led exercise, fitness instructor-led exercise,
yoga, and placebo (no particular intervention) and showed that all three
interventions were effective (as compared with placebo) in improving fatigue.
Additionally, the two exercise interventions showed also an effect on scores
related to objective physical disability [58]. Apart from these two trials, a
number of studies have been carried out and a recent Cochrane review has
concluded that there is a significant effect of exercise on fatigue outcomes in
people with MS [59••]. Besides, a recent study has found an association
between the improvement in fatigue levels after regular exercise in people with
MS and changes in the expression of genes related to modulation of systemic
response to interferon [60]. Although the results of this study need to be
replicated in larger cohorts, it provides a possible biological explanation for the
beneficial effect of exercise in MS [60].
Other physical approaches that have been evaluated include resistance
training, electromagnetic field therapy, and cooling therapy. Whereas resistance
training has shown a clear significant effect against placebo on MS-related
fatigue [18••], the evidence behind the other two approaches is too low to emit
recommendations in this regard [6, 61].
The psychological/cognitive approaches include cognitive behavioural
therapy, energy conservation education programmes and fatigue management,
and mindfulness intervention. Cognitive behavioural therapy aims to address
behaviours of people with MS in order to improve their levels of fatigue. Its
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efficacy has been proved in several studies and the NICE guidelines recommend
its use, either alone or in the context of more comprehensive programmes with
other non-pharmacological approaches [18••]. Regarding energy conservation
education programmes and fatigue management, these are approaches that try
to help he patient to save energy through the implementation of different
strategies such as work simplification or the use of labour-saving and ergo-
nomic equipment [3•]. Lastly, there are the mindfulness-based interventions,
which are based on Ban intentional and non-judgemental awareness of the
present moment^, as has been described in the literature [62, 63]. They derive
from Buddhist practice and have been used for a number of psychological and
somatic conditions, including MS-related fatigue. For that reason, their use is
currently recommended by the NICE guidelines, amongst other psychological
approaches [18••].
Finally, there are the mixed approaches, which combine both physical and
psychological interventions [3•]. The mixed programmes that are best known
are the FACETS (Fatigue: Applying Cognitive Behavioural and Energy effec-
tiveness Techniques to lifeStyle) [64••, 65••] and the EXIMS (pragmatic EXer-
cise Intervention in people with MS) [66••]. The FACETS was a very well
designed randomised placebo-controlled trial where 164 patients withMSwere
included and randomly assigned to FACETS plus usual care (current local
practice) or to usual care only. This study showed a beneficial effect of the
FACETS programme, which consisted of six weekly sessions of around 90 min,
on fatigue levels. Interestingly, this beneficial effect was observed after 1 and
4 months after finishing the intervention [64••] and was still maintained at
1 year of follow-up [65••]. Similarly, the EXIMS study was carried out in 120
patients with MS, who were randomly assigned to a 3-month exercise inter-
vention plus usual care or to usual care only. Its primary objective was to
evaluate the effect of a combined physical and psychological programme on the
self-reported exercise behaviour. Remarkably, the authors found that the pro-
gramme not only significantly improved the exercise behaviour but also was
associated with a decrease in fatigue levels [66••]. In relation to these results, it
is worth mentioning that the current NICE recommendations for patients with
MS and in particular with MS-related fatigue include not only physical or
cognitive interventions but also the promotion of long-term exercise [18••].
General considerations and conclusions
Fatigue is one of the most disabling symptoms in MS and needs an accurate
diagnosis and a rapid intervention. The assessment and treatment ofMS-related
fatigue may be complex, and it is mandatory to rule out potential causes or
triggers of fatigue. It is important to bear in mind that these causes may or may
not be directly related to MS so careful evaluations are mandatory.
Once primary causes of fatigue are ruled out, a multidisciplinary assessment
is necessary to ensure the patient receives the best therapeutic approach. Al-
though many drugs have been tested in multiple clinical trials, only those
trials with amantadine have provided enough evidence to allow the recom-
mendation of this treatment forMS-related fatigue. Yet its effect ismoderate and
the quality of that evidencemay be considered as low tomoderate, according to
the NICE guidelines. Undoubtedly, the scarcity of oral treatments able to
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improve the levels of MS-related fatigue in a satisfactory manner reflects our
poor understanding of the processes underlying fatigue in MS. Thus, more
research into this disabling symptom of MS is warranted.
Amongst all non-pharmacological approaches, the mixed physical and
psychological approaches deserve especial attention. They are naturally
comprehensive, and their corresponding clinical trials have shown prom-
ising results, which may translate into excellent results when applied in
clinical practice. These mixed approaches emphasise once again the need
for multidisciplinary teams and assessments. This should be taken into
account when new units specialised in MS and other neurodegenerative
disorders are being designed. Besides, the newly appeared mixed ap-
proaches promote other important aspects of the MS care, such as the
performance of regular exercise, which can have benefits potentially be-
yond the improvement of MS-related fatigue.
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